title: Is phosphodiesterase inhibition a relevant bronchospasmolytic principle?
authors.affiliation: Department of Pharmacology, Byk Gulden Pharmaceuticals, Konstanz.
authors.forename: U
authors.initials: U
authors.lastname: Kilian
authors.forename: R
authors.initials: R
authors.lastname: Beume
authors.forename: M
authors.initials: M
authors.lastname: Eltze
authors.forename: C
authors.initials: C
authors.lastname: Schudt
mesh_terms: D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D010276:Parasympatholytics / Q000494:pharmacology* / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D010276:Parasympatholytics; D010726:Phosphodiesterase Inhibitors